Femasys Inc (FEMY) — SEC Filings

Femasys Inc (FEMY) — 44 SEC filings. Latest: 8-K (Apr 1, 2026). Includes 32 8-K, 6 10-Q, 2 10-K.

View Femasys Inc on SEC EDGAR

Overview

Femasys Inc (FEMY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: On December 23, 2025, Femasys Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or transactions detailed in the provided excerpt. The company is incorporated in Delaware and headquartered in Suwanee, Georgia.

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 5 bearish, 38 neutral, 1 mixed. The dominant filing sentiment for Femasys Inc is neutral.

Filing Type Overview

Femasys Inc (FEMY) has filed 32 8-K, 6 10-Q, 1 S-1/A, 1 DEFA14A, 2 10-K, 1 DEF 14A, 1 10-K/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent SEC Filings (44)

Femasys Inc SEC Filing History
DateFormDescriptionRisk
Apr 1, 20268-K8-K Filing
Dec 23, 20258-KFemasys Inc. Files 8-K Reportlow
Dec 18, 20258-K8-K Filing
Nov 14, 202510-QFemasys Revenue Jumps 41% Amidst Expanding Global Approvals for FemBlochigh
Nov 10, 20258-KFemasys Inc. Files 8-K Reportlow
Nov 7, 20258-K8-K Filing
Nov 3, 20258-K8-K Filing
Oct 21, 20258-KFemasys Inc. Faces Delisting Concernshigh
Oct 17, 20258-KFemasys Inc. Reports Director/Officer Changes & Compensationmedium
Aug 27, 20258-KFemasys Inc. Files 8-K: Material Agreement & Equity Salesmedium
Aug 21, 2025S-1/AFemasys Files S-1/A for Equity Offering Amidst Funding Needshigh
Aug 20, 20258-KFemasys Inc. Files 8-K Reportlow
Aug 8, 202510-QFemasys Widens Losses Amid R&D Push, Revenue Declines 25%high
Aug 6, 20258-KFemasys Inc. Files 8-K Reportlow
Jul 18, 20258-KFemasys Inc. Faces Delisting Concernshigh
Jul 3, 20258-KFemasys Inc. Files 8-K: Material Agreement, Equity Sales, Financialsmedium
Jul 1, 20258-KFemasys Inc. Files 8-K Reportlow
Jun 25, 20258-KFemasys Inc. Files 8-K Reportlow
Jun 17, 20258-KFemasys Inc. Files 8-K Reportlow
Jun 2, 20258-KFemasys Inc. Files 8-K: Material Agreement, Equity Salesmedium

Risk Profile

Risk Assessment: Of FEMY's 39 recent filings, 6 were flagged as high-risk, 7 as medium-risk, and 26 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Femasys Inc Financial Summary (10-Q, Nov 14, 2025)
MetricValue
Revenue$1,479,926
Net Income-$14,677,582
Cash Position$4,569,038
Total Assets$16,290,153
Total Debt$11,733,902

Key Executives

  • Kathy Lee-Sepsick

Industry Context

Femasys Inc. operates in the women's health sector, specifically focusing on contraceptive and gynecological solutions. The market for long-acting reversible contraceptives (LARCs) and permanent birth control methods is growing, driven by demand for effective and convenient options. Key trends include innovation in device technology and increasing regulatory approvals for new products.

Top Tags

8-K (12) · sec-filing (10) · financials (9) · 8-k (8) · SEC Filing (6) · regulatory-filing (5) · Financials (4) · filing (4) · 10-Q (4) · delisting (3)

Key Numbers

Femasys Inc Key Metrics
MetricValueContext
SEC File Number001-40492Identifies the company's filing with the SEC.
EIN11-3713499Employer Identification Number for Femasys Inc.
Net Loss$14.68MIncreased from $13.69M in 2024 for the nine months ended September 30.
Sales Revenue$1.48MIncreased 41.28% from $1.05M in 2024 for the nine months ended September 30.
Cash and Cash Equivalents$4.57MIncreased from $3.45M at December 31, 2024, due to financing activities.
Accumulated Deficit$141.88MIncreased from $127.20M at December 31, 2024, reflecting ongoing losses.
Net Cash Provided by Financing Activities$16.06MCrucial for funding operations, up from $1.00M in 2024.
Net Cash Used in Operating Activities$14.51MSlightly increased from $14.37M in 2024, indicating continued cash burn.
Common Shares Outstanding47,302,373As of September 30, 2025, significantly increased from 23,355,926 at December 31, 2024, due to equity financings.
Revenue Growth41.28%Year-over-year increase for the nine months ended September 30.
Research and Development Expenses$5.76MDecreased from $6.05M in 2024 for the nine months ended September 30.
Sales and Marketing Expenses$3.04MIncreased from $2.85M in 2024 for the nine months ended September 30.
Shares of Common Stock Offered11,428,571Maximum number of common shares offered in the S-1/A
Pre-Funded Warrants Offered11,428,571Maximum number of pre-funded warrants offered
Common Warrants Offered11,428,571Maximum number of common warrants offered

Related Companies

FYS · FYNS · FEMASYS INC

Frequently Asked Questions

What are the latest SEC filings for Femasys Inc (FEMY)?

Femasys Inc has 44 recent SEC filings from Feb 2024 to Apr 2026, including 32 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of FEMY filings?

Across 44 filings, the sentiment breakdown is: 5 bearish, 38 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Femasys Inc SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Femasys Inc (FEMY) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Femasys Inc?

Key financial highlights from Femasys Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for FEMY?

The investment thesis for FEMY includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Femasys Inc?

Key executives identified across Femasys Inc's filings include Kathy Lee-Sepsick.

What are the main risk factors for Femasys Inc stock?

Of FEMY's 39 assessed filings, 6 were flagged high-risk, 7 medium-risk, and 26 low-risk.

What are recent predictions and forward guidance from Femasys Inc?

Forward guidance and predictions for Femasys Inc are extracted from SEC filings as they are enriched.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.